Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Abstract

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov number, NCT00045032.)

Keywords

TrastuzumabMedicineBreast cancerOncologyChemotherapyAdjuvantMonoclonal antibodyInternal medicineAdjuvant chemotherapyCancerStage (stratigraphy)AntibodyImmunology

Affiliated Institutions

Related Publications

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz , Chiun‐Sheng Huang , Max S. Mano +26 more

Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer...

2018 New England Journal of Medicine 2430 citations

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Harold J. Burstein , Lyndsay N. Harris , P. Kelly Marcom +15 more

Purpose: Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. We conducted a multicenter p...

2003 Journal of Clinical Oncology 343 citations

Disease-Free Survival According to Degree of <i>HER2</i> Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

Mitch Dowsett , Marion Procter , Worta McCaskill‐Stevens +11 more

Purpose To determine whether (1) immunohistochemical (IHC) HER2 status (ie, 2+ or 3+), (2) degree of fluorescence in situ hybridization (FISH) amplification according to (2a) HE...

2009 Journal of Clinical Oncology 184 citations

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Joseph A. Sparano , Robert J. Gray , Della Makower +27 more

Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a...

2018 New England Journal of Medicine 2202 citations

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi , Cristina Saura , Toshinari Yamashita +22 more

Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppressi...

2019 New England Journal of Medicine 1788 citations

Publication Info

Year: 2005
Type: article
Volume: 353
Issue: 16
Pages: 1659-1672
Citations: 5034
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5034

OpenAlex

Cite This

APA Style

                            
                                
                                    Martine Piccart, 
                                
                                    Marion Procter, 
                                
                                    Brian Leyland‐Jones
                                
                                et al.
                            
                            (2005). 
                            Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. 
                            New England Journal of Medicine
                            , 353
                            (16)
                            , 1659-1672.
                            https://doi.org/10.1056/nejmoa052306
                        

Identifiers

DOI: 10.1056/nejmoa052306